{"entity":{"id":"nct07108504","kind":"trial","name":"Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of gemcitabine and LM-302 in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.","summary":"Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT07108504 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 30 participants, started 2025-08-10 and due to reach its primary completion in 2026-08-10. Interventions recorded: Gemcitabine; LM-302. Conditions listed: Pancreatic Cancer; Chemotherapy Effect. Primary outcome: Objective Response Rate (ORR) per RECIST 1.1. Pancreatic eligibility wording from the registry: \"Histologically or cytologically confirmed unresectable, locally advanced, or metastatic pancreatic ductal adenocarcinoma (PDAC) not amenable to curative treatment\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07108504","url":"https://clinicaltrials.gov/study/NCT07108504"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["gemcitabine","lm-302"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07108504","phase":"2","setting":"An Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of LM-302 Combined With Gemcitabine as Second-line Treatment for CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer","sponsor":"Shanghai Zhongshan Hospital","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07108504/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"lm-302","kind":"drug","name":"LM-302","route":"/drugs/lm-302/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}